GlassScriptPhysician profile
Mallory E Tagge
NPI 1548636293
$5,203.37
in general payments reported to CMS, 2019-2025
26 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,393 · 2022: $1,361 · 2023: $1,113 · 2024: $517 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $656.65 | 2021-2024 | Belbuca |
| Abbott Laboratories | $625.54 | 2021-2025 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606.34 | 2021-2024 | Relistor |
| Grt US Holding, INC. | $513.13 | 2021-2022 | |
| Saluda Medical Americas, INC. | $491.21 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $452.15 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Forte Bio-Pharma LLC | $370.10 | 2022-2023 | Prolate, Nalocet |
| Biodelivery Sciences International, INC. | $287.80 | 2021 | |
| Scilex Pharmaceuticals INC. | $187.45 | 2021-2023 | Ztlido |
| Averitas Pharma INC. | $180.66 | 2023-2025 | Qutenza |
| Nalu Medical, INC. | $156.27 | 2022 | |
| Vertos Medical, INC. | $136.52 | 2022 | |
| Ibsa Pharma INC. | $75.36 | 2021-2023 | Tirosint, Licart |
| Eisai INC. | $67.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $66.02 | 2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $63.98 | 2025 | Sprint Pns System |
| Redhill Biopharma INC. | $56.09 | 2021 | |
| Azurity Pharmaceuticals, INC. | $51.85 | 2023-2024 | Horizant, Horizant, Edarbi |
| Abbvie INC. | $38.79 | 2021-2024 | |
| Boston Scientific Corporation | $35.49 | 2022-2025 | Intracept |
| Bioventus LLC | $17.26 | 2024 | Durolane |
| Arbor Pharmaceuticals, INC. | $15.17 | 2021 | |
| Amgen INC. | $14.90 | 2025 | Evenity, Prolia |
| Nevro Corp. | $13.39 | 2022 | |
| Almatica Pharma LLC | $12.18 | 2021 | |
| Pacira Therapeutics, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Tagge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.